2 Mar 2020 15:35
Oncimmune Holdings plc
Â
("Oncimmune" or the "Company")
Â
Director/PDMR's Dealing
Â
Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, announces the following dealing in the Company's ordinary shares of £0.01 each in the Company ("Ordinary Shares") by Carsten Schroeder, PDMR and Non-Executive Director. The Company was notified on 28 February 2020.
Â
PDMR | Date of purchase | Number of shares purchased | Purchase price | Total shares held | % ISC held followingpurchase |
Carsten Schroeder | 28 February 2020 | 9,000 | £0.541 | 9,000 | 0.00014% |
Â
This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.
Â
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
Â
1  | Details of the person discharging managerial responsibilities / person closely associated  | ||||
a)  | Name   | Carsten Schroeder | |||
2  | Reason for the notification  | ||||
a)  | Position/status   | Non-Executive Director | |||
b)  | Initial notification /Amendment   | Initial notification | |||
3  | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  | ||||
a)  | Name   | Oncimmune Holdings plc | |||
b) Â | LEI Â Â | 213800HCYIWT6YPI1I02Â | |||
4  | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted   | ||||
a)  | Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each  | |||
Identification code | ISIN: GB00BYQ94H38 | ||||
b)  | Nature of the transaction   | Purchase of shares | |||
c) Â | Price(s) and volume(s) | ||||
Price | Volume | ||||
0.541 GBP | 9,000 | ||||
d) Â | Aggregated information | ||||
- Aggregated volume | Same as above | ||||
- Price | |||||
e)  | Date of the transaction   | 28 February 2020 | |||
f)  | Place of the transaction   | London stock exchange, AIM |
Â
For further information:
Â
Oncimmune Holdings plc
Andrew Stewart, General Counsel and Company Secretary
contact@oncimmune.comÂ
Â